Asset Details
Do you wish to reserve the book?
Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure
Do you wish to request the book?
Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure
2018
Overview
Mechanisms of maintenance of both atrial fibrillation and structural left ventricular disease are known to include fibrosis. Galectin-3, a biomarker of fibrosis, is elevated both in patients with heart failure and persistent atrial fibrillation. We sought to find whether galectin-3 has a prognostic value in patients with heart failure and a reduced left ventricular ejection fraction undergoing ablation of persistent atrial fibrillation.
Serum concentrations of galectin-3 were determined in a consecutive series of patients with an ejection fraction ≤40%, addressed for ablation of persistent atrial fibrillation. Responders to ablation were patients in sinus rhythm and with an ejection fraction ≥50% at 6 months. A combined endpoint of heart failure hospitalization, transplantation and/or death was used at 12 months.
Seventy-five patients were included (81% male, age 63±10 years, ejection fraction 34±7%, galectin-3 21±12 ng/mL). During follow-up, eight patients were hospitalized for decompensated heart failure, 1 underwent heart transplantation, and 4 died; 50 patients were considered as responders to ablation. After adjustment, galectin-3 level independently predicted both 6-month absence of response to ablation (OR = 0.89 per unit increase, p = 0.002). Patients with galectin-3 levels <26 had a 95% 1-year event-free survival versus 46% in patients with galectin-3 ≥26 ng/mL (p<0.0001).
Galectin-3 levels independently predict outcomes in patients with reduced left ventricular systolic function addressed for ablation of persistent AF, and may be of interest in defining the therapeutic strategy in this population.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Aged
/ Atrial Fibrillation - diagnosis
/ Atrial Fibrillation - surgery
/ Female
/ Fibrosis
/ Heart
/ Heart Failure, Systolic - blood
/ Heart Failure, Systolic - diagnosis
/ Heart Failure, Systolic - surgery
/ Humanities and Social Sciences
/ Humans
/ Male
/ Medicine and Health Sciences
/ NMR
/ Patients
